Broadly neutralizing monoclonal antibodies (bNAbs) 2F5 and 4E10 bind to the membrane proximal external region (MPER) of gp41 and also cross-react with phospholipids. In this study, we investigated if chemical modifications on theMPER adjacent to 2F5 and 4E10 epitopes using mimetics of inflammation-associated posttranslational modifications to induce 2F5- and 4E10-like bNAbs can break tolerance. We synthesized a series of chemically modified peptides spanning theMPER. The serine, threonine, and tyrosine residues in the peptides were modified with sulfate, phosphate, or nitrate moieties and presented in liposomes for rabbit immunizations. All immunizations resulted in high antisera titers directed toward both the modified and unmodified immun...
Synthetic peptides were used as tools in order to study various characteristic sof human immunodefic...
Ten to 30% of HIV-1 infected subjects develop broadly neutralizing antibodies (bNAbs) during chronic...
The development of an effective HIV vaccine is hindered by several obstacles. One of the leading cha...
Broadly neutralizing monoclonal antibodies (bNAbs) 2F5 and 4E10 bind to the membrane proximal extern...
The inability to generate broadly neutralizing antibody (bnAb) responses to the membrane proximal ex...
M.Sc.It is generally believed that the development of a completely effective vaccine for the human i...
The membrane proximal region (MPR) of HIV-1 gp41 is a desirable candidate for development of a vacci...
The membrane proximal external region (MPER) of HIV-1 gp41 is targeted by broadly neutralizing antib...
The membrane proximal external region (MPER) of the fusogenic HIV-1 glycoprotein-41 harbors the epit...
A fundamental challenge for developing an effective and safe HIV-1 vaccine is to identify vaccine im...
Envelope glycoproteins, gp120 and gp41, of the human immunodeficiency virus type 1 (HIV-1) elicit im...
13 p.The membrane proximal external region (MPER) of the fusogenic HIV-1 glycoprotein-41 harbors the...
The envelope glycoprotein (Env) of Human Immunodeficiency Virus 1 (HIV-1) has developed several immu...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
International audienceThe design of immunogens susceptible to elicit potent and broadly neutralizing...
Synthetic peptides were used as tools in order to study various characteristic sof human immunodefic...
Ten to 30% of HIV-1 infected subjects develop broadly neutralizing antibodies (bNAbs) during chronic...
The development of an effective HIV vaccine is hindered by several obstacles. One of the leading cha...
Broadly neutralizing monoclonal antibodies (bNAbs) 2F5 and 4E10 bind to the membrane proximal extern...
The inability to generate broadly neutralizing antibody (bnAb) responses to the membrane proximal ex...
M.Sc.It is generally believed that the development of a completely effective vaccine for the human i...
The membrane proximal region (MPR) of HIV-1 gp41 is a desirable candidate for development of a vacci...
The membrane proximal external region (MPER) of HIV-1 gp41 is targeted by broadly neutralizing antib...
The membrane proximal external region (MPER) of the fusogenic HIV-1 glycoprotein-41 harbors the epit...
A fundamental challenge for developing an effective and safe HIV-1 vaccine is to identify vaccine im...
Envelope glycoproteins, gp120 and gp41, of the human immunodeficiency virus type 1 (HIV-1) elicit im...
13 p.The membrane proximal external region (MPER) of the fusogenic HIV-1 glycoprotein-41 harbors the...
The envelope glycoprotein (Env) of Human Immunodeficiency Virus 1 (HIV-1) has developed several immu...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
International audienceThe design of immunogens susceptible to elicit potent and broadly neutralizing...
Synthetic peptides were used as tools in order to study various characteristic sof human immunodefic...
Ten to 30% of HIV-1 infected subjects develop broadly neutralizing antibodies (bNAbs) during chronic...
The development of an effective HIV vaccine is hindered by several obstacles. One of the leading cha...